COMP <GO>
CLDX vs IDXX // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Celldex Therapeutics Inc. (NASDAQ) VS. IDEXX Laboratories Inc. (NASDAQ) • 15-METRIC TALLY: CLDX 1
— IDXX 9
■ METRIC PARITY
LAST: $29.04 (-3.52%) • MKT CAP: $2.36B
options-implied-move
—
LAST: $671.64 (+21.85%) • MKT CAP: $43.42B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLDX VS. IDXX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLDX | IDXX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.10% | 61.80% | +25.30 | CLDX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.60% | -64.60 | IDXX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 31.1x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.10% | 2.33% | -11.43 | IDXX | /fcf-yield <GO> |
| Operating Margin | -60.00% | 31.60% | -91.60 | IDXX | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 24.60% | -84.60 | IDXX | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 10.40% | -75.40 | IDXX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 20.25 | 20.99 | -0.74 | IDXX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 9/9 | -6.00 | IDXX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.7 | 50.5 | -4.80 | IDXX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.89 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 39.8x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.36B | $43.42B | -$41.06B | IDXX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLDX REV | IDXX REV | CLDX GROSS % | IDXX GROSS % | CLDX FCF | IDXX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.5M | $4.30B | 87.1% | 61.8% | -$213.7M | $1.06B |
| FY 2024 | $7.0M | $3.90B | 97.2% | 61.0% | -$159.7M | $808.1M |
| FY 2023 | $6.9M | $3.66B | — | — | -$107.3M | $741.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLDX // BETA —
IDXX // BETA 0.89